Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting the use of a specific screening strategy to identify stocks with strong fundamentals and positive price momentum. Group 1: Stock Screening Strategy - The "Recent Price Strength" screen is designed to identify stocks with sufficient fundamental strength to maintain their recent uptrend, focusing on those trading in the upper portion of their 52-week high-low range, indicating bullishness [3][4]. - Delcath Systems, Inc. (DCTH) is highlighted as a strong candidate for trend investing, having increased by 15.8% over the past 12 weeks, reflecting investor confidence [4]. - DCTH has also shown a price increase of 4.7% over the last four weeks, indicating that the upward trend is still intact [5]. Group 2: Fundamental Strength - DCTH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), suggesting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Market Insights - The article suggests that the price trend for DCTH is unlikely to reverse soon, and encourages investors to consider other stocks that meet the criteria of the "Recent Price Strength" screen [8]. - The Zacks Rank stock-rating system has a proven track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, indicating the effectiveness of this rating system in identifying potential winners [7].

Core Viewpoint - Delcath Systems, Inc. preannounced Q3 sales results, reporting $10 million in the US and $1.2 million in Europe, indicating a significant performance in the US market [1] Group 1: Sales Performance - Q3 sales in the US reached $10 million, showcasing strong market demand [1] - European sales amounted to $1.2 million, contributing to the overall revenue [1]

Group 1 - The article discusses Delcath Systems (NASDAQ: DCTH) and its progress towards submitting a New Drug Application (NDA) for its melphalan drug/device kit, highlighting the company's efforts over the past three years [1] - The author emphasizes their long position in DCTH shares, indicating a personal investment interest in the company's future performance [2] - The article is part of a broader investment research service called Compounding Healthcare, which focuses on innovative healthcare companies and potential investment opportunities [1]

Delcath Systems Inc (NASDAQ:DCTH) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephens Swayampakula Ramakanth - H.C. Wainwright John Newman - Canaccord Genuity Corp Yale Jen - Laidlaw & Company Chase K ...

Core Insights - Delcath Systems, Inc. (DCTH) reported a quarterly loss of $0.03 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.13, and an improvement from a loss of $0.61 per share a year ago, indicating a 76.92% earnings surprise [1] - The company achieved revenues of $11.2 million for the quarter ended September 2024, aligning with the Zacks Consensus Estimate and showing a substantial increase from $0.43 million in the same quarter last year [2] - Delcath Systems shares have increased approximately 163% year-to-date, outperforming the S&P 500's gain of 25.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.16 on projected revenues of $11.35 million, while for the current fiscal year, the estimate is -$1.64 on revenues of $33.45 million [7] - The estimate revisions trend for Delcath Systems is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Delcath Systems belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Stereotaxis Inc. (STXS), is expected to report a quarterly loss of $0.05 per share, reflecting a year-over-year change of +28.6%, with revenues anticipated to be $6.8 million, down 12.8% from the previous year [9][10]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 10-Q ______________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-16133 ______________________ DELCATH SYSTEMS, I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $.01 par value DCTH The Nasdaq Capital Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 DELCATH SYSTEMS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-16133 06-1245881 (State or other jurisdiction of inc ...

Delcath Systems, Inc. (DCTH) closed the last trading session at $10.77, gaining 26.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $21.20 indicates a 96.8% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $2.59. While the lowest estimate of $18 indicates a 67.1% increase from the current price level, the most optimistic anal ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

Delcath Systems, Inc. (DCTH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...